RPG Life Sciences Limited (RPGLIFE) - Net Assets

Latest as of March 2026: Rs6.05 Billion INR ≈ $65.47 Million USD

Based on the latest financial reports, RPG Life Sciences Limited (RPGLIFE) has net assets worth Rs6.05 Billion INR (≈ $65.47 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs7.93 Billion ≈ $85.78 Million USD) and total liabilities (Rs1.88 Billion ≈ $20.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RPG Life Sciences Limited tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs6.05 Billion
% of Total Assets	76.32%
Annual Growth Rate	19.23%
5-Year Change	136.68%
10-Year Change	292.88%
Growth Volatility	72.57

RPG Life Sciences Limited - Net Assets Trend (2005–2026)

This chart illustrates how RPG Life Sciences Limited's net assets have evolved over time, based on quarterly financial data. See RPGLIFE defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for RPG Life Sciences Limited (2005–2026)

The table below shows the annual net assets of RPG Life Sciences Limited from 2005 to 2026. For live valuation and market cap data, see RPG Life Sciences Limited market capitalisation.

Year	Net Assets	Change
2026-03-31	Rs6.05 Billion ≈ $65.47 Million	+14.10%
2025-03-31	Rs5.31 Billion ≈ $57.37 Million	+41.53%
2024-03-31	Rs3.75 Billion ≈ $40.54 Million	+21.86%
2023-03-31	Rs3.08 Billion ≈ $33.27 Million	+20.26%
2022-03-31	Rs2.56 Billion ≈ $27.66 Million	+18.17%
2021-03-31	Rs2.16 Billion ≈ $23.41 Million	+22.59%
2020-03-31	Rs1.77 Billion ≈ $19.10 Million	+10.01%
2019-03-31	Rs1.60 Billion ≈ $17.36 Million	+3.72%
2018-03-31	Rs1.55 Billion ≈ $16.74 Million	+0.43%
2017-03-31	Rs1.54 Billion ≈ $16.66 Million	+15.34%
2016-03-31	Rs1.34 Billion ≈ $14.45 Million	+6.74%
2015-03-31	Rs1.25 Billion ≈ $13.54 Million	-0.48%
2014-03-31	Rs1.26 Billion ≈ $13.60 Million	+64.97%
2013-03-31	Rs762.30 Million ≈ $8.24 Million	+2.82%
2012-03-31	Rs741.40 Million ≈ $8.02 Million	-0.92%
2011-03-31	Rs748.31 Million ≈ $8.09 Million	+16.14%
2010-03-31	Rs644.31 Million ≈ $6.97 Million	+17.32%
2009-03-31	Rs549.21 Million ≈ $5.94 Million	+11.62%
2008-03-31	Rs492.02 Million ≈ $5.32 Million	-33.72%
2007-03-31	Rs742.36 Million ≈ $8.03 Million	+11.18%
2006-03-31	Rs667.72 Million ≈ $7.22 Million	+343.37%
2005-03-31	Rs150.60 Million ≈ $1.63 Million	--

Equity Component Analysis

This analysis shows how different components contribute to RPG Life Sciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 30618800000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Common Stock	Rs132.30 Million	2.19%
Other Components	Rs5.92 Billion	97.81%
Total Equity	Rs6.05 Billion	100.00%

RPG Life Sciences Limited Competitors by Market Cap

The table below lists competitors of RPG Life Sciences Limited ranked by their market capitalization.

Company	Market Cap
Lets Holding Group Co Ltd SHE:002398	$407.55 Million
Entree Resources Ltd TO:ETG	$407.56 Million
TARC Limited NSE:TARC	$407.73 Million
Zhengzhou J and T Hi Tech Co SHE:300845	$407.74 Million
Banco Santander Brasil SA BA:BSBR	$407.38 Million
IOL Chemicals and Pharmaceuticals Limited NSE:IOLCP	$407.27 Million
Build-A-Bear Workshop Inc NYSE:BBW	$407.23 Million
Caleres Inc NYSE:CAL	$406.91 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in RPG Life Sciences Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 5,305,300,000 to 6,053,500,000, a change of 748,200,000 (14.1%).
Net income of 1,151,700,000 contributed positively to equity growth.
Dividend payments of 396,900,000 reduced retained earnings.
Other comprehensive income decreased equity by 86,800,000.
Other factors increased equity by 80,200,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs1.15 Billion	+19.03%
Dividends Paid	Rs396.90 Million	-6.56%
Other Comprehensive Income	Rs-86.80 Million	-1.43%
Other Changes	Rs80.20 Million	+1.32%
Total Change	Rs-	14.10%

Book Value vs Market Value Analysis

This analysis compares RPG Life Sciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 6.22x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 188.01x to 6.22x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-03-31	Rs12.12	Rs2278.10	x
2006-03-31	Rs53.67	Rs2278.10	x
2007-03-31	Rs51.67	Rs2278.10	x
2008-03-31	Rs34.62	Rs2278.10	x
2009-03-31	Rs38.19	Rs2278.10	x
2010-03-31	Rs39.03	Rs2278.10	x
2011-03-31	Rs45.26	Rs2278.10	x
2012-03-31	Rs44.83	Rs2278.10	x
2013-03-31	Rs46.10	Rs2278.10	x
2014-03-31	Rs76.05	Rs2278.10	x
2015-03-31	Rs75.69	Rs2278.10	x
2016-03-31	Rs80.79	Rs2278.10	x
2017-03-31	Rs93.16	Rs2278.10	x
2018-03-31	Rs93.57	Rs2278.10	x
2019-03-31	Rs97.04	Rs2278.10	x
2020-03-31	Rs106.76	Rs2278.10	x
2021-03-31	Rs130.87	Rs2278.10	x
2022-03-31	Rs154.65	Rs2278.10	x
2023-03-31	Rs185.98	Rs2278.10	x
2024-03-31	Rs226.65	Rs2278.10	x
2025-03-31	Rs320.79	Rs2278.10	x
2026-03-31	Rs366.04	Rs2278.10	x

Capital Efficiency Dashboard

This dashboard shows how efficiently RPG Life Sciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 19.03%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 16.28%
• Asset Turnover: 0.89x
• Equity Multiplier: 1.31x
Recent ROE (19.03%) is above the historical average (9.30%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	-144.22%	-17.29%	0.53x	15.62x	Rs-232.25 Million
2006	38.55%	17.84%	0.66x	3.29x	Rs190.64 Million
2007	10.83%	6.68%	0.59x	2.77x	Rs6.13 Million
2008	12.10%	4.66%	0.73x	3.57x	Rs10.33 Million
2009	12.03%	4.70%	0.84x	3.06x	Rs11.15 Million
2010	16.76%	6.75%	0.96x	2.60x	Rs43.53 Million
2011	16.99%	6.90%	0.96x	2.55x	Rs52.29 Million
2012	1.15%	0.44%	1.05x	2.47x	Rs-65.64 Million
2013	5.79%	1.99%	1.08x	2.70x	Rs-32.13 Million
2014	42.46%	22.69%	1.20x	1.56x	Rs408.24 Million
2015	0.80%	0.41%	1.23x	1.57x	Rs-115.16 Million
2016	8.70%	4.17%	1.36x	1.54x	Rs-17.39 Million
2017	13.28%	6.68%	1.24x	1.60x	Rs50.52 Million
2018	8.69%	3.99%	1.16x	1.88x	Rs-20.25 Million
2019	6.74%	3.34%	1.29x	1.57x	Rs-52.40 Million
2020	16.43%	7.86%	1.38x	1.51x	Rs113.53 Million
2021	18.48%	10.43%	1.26x	1.40x	Rs183.55 Million
2022	20.13%	11.78%	1.27x	1.35x	Rs259.03 Million
2023	21.99%	13.29%	1.21x	1.36x	Rs368.80 Million
2024	23.39%	15.18%	1.13x	1.37x	Rs501.75 Million
2025	34.54%	28.04%	0.99x	1.24x	Rs1.30 Billion
2026	19.03%	16.28%	0.89x	1.31x	Rs546.35 Million

Industry Comparison

This section compares RPG Life Sciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $41,118,163,484
Average return on equity (ROE) among peers: 13.86%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
RPG Life Sciences Limited (RPGLIFE)	Rs6.05 Billion	-144.22%	0.31x	$407.47 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$366.97 Million	3.51%	2.41x	$25.11 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.23 Billion	12.93%	2.27x	$365.36 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$2.31 Million	-8.08%	0.08x	$645.54 Million
Abbott India Limited (ABBOTINDIA)	$2.31 Billion	29.62%	0.43x	$6.01 Billion
Ajanta Pharma Limited (AJANTPHARM)	$32.64 Billion	21.83%	0.24x	$4.15 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$7.23 Billion	13.11%	3.52x	$996.26 Million
Alkem Laboratories Limited (ALKEM)	$75.58 Billion	20.97%	0.52x	$6.95 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.09 Billion	18.92%	0.29x	$170.62 Million
Alembic Pharmaceuticals Limited (APLLTD)	$22.20 Billion	18.58%	0.77x	$1.59 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$268.52 Billion	7.18%	0.49x	$8.98 Billion

About RPG Life Sciences Limited

NSE:RPGLIFE India Drug Manufacturers - Specialty & Generic

Market Cap

$407.47 Million

Rs37.68 Billion INR

Market Cap Rank

#13445 Global

#666 in India

Share Price

Rs2278.10

Change (1 day)

-1.04%

52-Week Range

Rs1744.00 - Rs2657.80

All Time High

Rs2828.55